This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ME 23andMe (ME) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesInsider TradesTrendsBuy This Stock About 23andMe Stock (NASDAQ:ME) Get 23andMe alerts:Sign Up Key Stats Today's Range$0.61▼$0.6150-Day Range$0.50▼$0.5052-Week Range$0.53▼$9.57VolumeN/AAverage Volume1.57 million shsMarket Capitalization$16.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. Read More Receive ME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 23andMe and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ME Stock News HeadlinesThe company failed to implement basic defenses: 23andMe data breach victims are finally getting paid, but bankruptcy could shrink their payoutsAugust 9, 2026 | msn.com23andMe was hacked — here's how much lawyers could get for settling consumer lawsuitsAugust 6, 2026 | bizjournals.comGold buyout deals have handed shareholders overnight gains up to 79 percentGold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,228.6% for shareholders of companies like G2 Goldfields, Loncor Gold, and Rupert Resources. Analyst Garrett Goggin, CFA, CMT, tracks which small miners hold the grade, cash flow, and assets that attract buyout interest from major producers. One quarter of his tracked portfolio has already been acquired as the gold bull market's M and A phase accelerates. | Golden Portfolio (Ad)New 23andMe Research Institute Study First to Identify Association Between Specific Side Effects from Common Antidepressants and GeneticsAugust 5, 2026 | markets.businessinsider.comThe dark side of 23andMe you'll wish you knew about soonerAugust 4, 2026 | msn.comArkansas receives $431K in 23andMe settlement: AG GriffinJuly 27, 2026 | yahoo.comAG Griffin announces multistate settlement with 23andMe over genetic data breachJuly 27, 2026 | msn.comArkansas to receive $431K in multistate settlement with 23andMe over genetic data breachJuly 27, 2026 | msn.comSee More Headlines ME Stock Analysis - Frequently Asked Questions How were 23andMe's earnings last quarter? 23andMe Holding Co. (NASDAQ:ME) posted its earnings results on Tuesday, January, 28th. The company reported ($1.02) earnings per share (EPS) for the quarter. 23andMe had a negative trailing twelve-month return on equity of 170.07% and a negative net margin of 183.39%. When did 23andMe's stock split? 23andMe shares reverse split on the morning of Wednesday, October 16th 2024.The 1-20 reverse split was announced on Friday, October 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of 23andMe own? Based on aggregate information from My MarketBeat watchlists, some other companies that 23andMe investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings1/28/2025Today8/15/2026Fiscal Year End3/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ME CIK1804591 Webvgacquisition.com Phone650-938-6300FaxN/AEmployees770Year Founded2006Profitability EPS (Trailing Twelve Months)($15.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$666.70 million Net Margins-183.39% Pretax Margin-186.76% Return on Equity-170.07% Return on Assets-62.13% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio0.91 Sales & Book Value Annual Sales$208.78 million Price / Sales0.08 Cash Flow$0.65 per share Price / Cash Flow0.93 Book Value$2.34 per share Price / Book0.26Miscellaneous Outstanding Shares26,827,000Free Float19,766,000Market Cap$16.27 million OptionableNot Optionable Beta1.19 Social Links 10 Best Stocks to Own - Summer 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:ME) was last updated on 8/16/2026 by MarketBeat.com Staff. From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredThe Greatest Wealth Transfer Since the Internet Boom Just StartedWall Street forensic accountant Joel Litman - who flagged the 2008 crash months early and called the 2020 COVI...Altimetry | SponsoredYour 10X AI demo is starting…Keith Kaplan, the AI expert behind tools used by more than 100000 investors, built his models with an investme...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredRay Dalio: Buy Gold. Get Paid.Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
